Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Subcutaneous Zalunfiban (RUC-4) in Healthy Volunteers and Stable CAD
NCT03844191Phase 1Completed
- Sponsor
- CeleCor Therapeutics
- Start
- Feb 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of zalunfiban in coronary artery disease (CAD) (5 arms), sponsored by CeleCor Therapeutics. Primary endpoint: Platelet Inhibition at 24 hours. Started Feb 2019; status: completed.
02
Drugs
zalunfiban
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03844191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844191.